206 related articles for article (PubMed ID: 18183490)
1. Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses.
Evans CO; Moreno CS; Zhan X; McCabe MT; Vertino PM; Desiderio DM; Oyesiku NM
Pituitary; 2008; 11(3):231-45. PubMed ID: 18183490
[TBL] [Abstract][Full Text] [Related]
2. Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses.
Moreno CS; Evans CO; Zhan X; Okor M; Desiderio DM; Oyesiku NM
Cancer Res; 2005 Nov; 65(22):10214-22. PubMed ID: 16288009
[TBL] [Abstract][Full Text] [Related]
3. Giant pituitary adenomas: pathologic-radiographic correlations and lack of role for p53 and MIB-1 labeling.
Madsen H; Borges TM; Knox AJ; Michaelis KA; Xu M; Lillehei KO; Wierman ME; Kleinschmidt-DeMasters BK
Am J Surg Pathol; 2011 Aug; 35(8):1204-13. PubMed ID: 21753697
[TBL] [Abstract][Full Text] [Related]
4. Ras mutations in human pituitary tumors.
Karga HJ; Alexander JM; Hedley-Whyte ET; Klibanski A; Jameson JL
J Clin Endocrinol Metab; 1992 Apr; 74(4):914-9. PubMed ID: 1312542
[TBL] [Abstract][Full Text] [Related]
5. Patterns of gene expression in pituitary carcinomas and adenomas analyzed by high-density oligonucleotide arrays, reverse transcriptase-quantitative PCR, and protein expression.
Ruebel KH; Leontovich AA; Jin L; Stilling GA; Zhang H; Qian X; Nakamura N; Scheithauer BW; Kovacs K; Lloyd RV
Endocrine; 2006 Jun; 29(3):435-44. PubMed ID: 16943582
[TBL] [Abstract][Full Text] [Related]
6. microRNA expression profile and differentially-expressed genes in prolactinomas following bromocriptine treatment.
Wang C; Su Z; Sanai N; Xue X; Lu L; Chen Y; Wu J; Zheng W; Zhuge Q; Wu ZB
Oncol Rep; 2012 May; 27(5):1312-20. PubMed ID: 22366961
[TBL] [Abstract][Full Text] [Related]
7. Analysis of differential gene expression by fiber-optic BeadArray and pathway in prolactinomas.
Jiang Z; Gui S; Zhang Y
Endocrine; 2010 Dec; 38(3):360-8. PubMed ID: 20972730
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of prolactinomas.
Spada A; Mantovani G; Lania A
Pituitary; 2005; 8(1):7-15. PubMed ID: 16411063
[TBL] [Abstract][Full Text] [Related]
9. Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
Gao H; Wang F; Lan X; Li C; Feng J; Bai J; Cao L; Gui S; Hong L; Zhang Y
BMC Cancer; 2015 Apr; 15():272. PubMed ID: 25884948
[TBL] [Abstract][Full Text] [Related]
10. Analysis of differential gene expression using fiber-optic bead array and pathway analyses in pituitary adenomas.
Jiang Z; Gui S; Zhang Y
J Clin Neurosci; 2011 Oct; 18(10):1386-91. PubMed ID: 21802306
[TBL] [Abstract][Full Text] [Related]
11. Differential gene expression in pituitary adenomas by oligonucleotide array analysis.
Morris DG; Musat M; Czirják S; Hanzély Z; Lillington DM; Korbonits M; Grossman AB
Eur J Endocrinol; 2005 Jul; 153(1):143-51. PubMed ID: 15994756
[TBL] [Abstract][Full Text] [Related]
12. Reexpression of p8 contributes to tumorigenic properties of pituitary cells and appears in a subset of prolactinomas in transgenic mice that hypersecrete luteinizing hormone.
Mohammad HP; Seachrist DD; Quirk CC; Nilson JH
Mol Endocrinol; 2004 Oct; 18(10):2583-93. PubMed ID: 15243129
[TBL] [Abstract][Full Text] [Related]
13. Nuclear accumulation of e-cadherin correlates with loss of cytoplasmic membrane staining and invasion in pituitary adenomas.
Elston MS; Gill AJ; Conaglen JV; Clarkson A; Cook RJ; Little NS; Robinson BG; Clifton-Bligh RJ; McDonald KL
J Clin Endocrinol Metab; 2009 Apr; 94(4):1436-42. PubMed ID: 19158195
[TBL] [Abstract][Full Text] [Related]
14. Relationship between expression of vascular endothelial growth factor and the proliferation of prolactinomas.
Li N; Jiang Z
Clin Neurol Neurosurg; 2017 Feb; 153():102-106. PubMed ID: 28110235
[TBL] [Abstract][Full Text] [Related]
15. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas.
Zhang X; Horwitz GA; Heaney AP; Nakashima M; Prezant TR; Bronstein MD; Melmed S
J Clin Endocrinol Metab; 1999 Feb; 84(2):761-7. PubMed ID: 10022450
[TBL] [Abstract][Full Text] [Related]
16. Expression of prolactin-releasing peptide and its receptor messenger ribonucleic acid in normal human pituitary and pituitary adenomas.
Zhang X; Danila DC; Katai M; Swearingen B; Klibanski A
J Clin Endocrinol Metab; 1999 Dec; 84(12):4652-5. PubMed ID: 10599733
[TBL] [Abstract][Full Text] [Related]
17. ras mutations in human prolactinomas and pituitary carcinomas.
Cai WY; Alexander JM; Hedley-Whyte ET; Scheithauer BW; Jameson JL; Zervas NT; Klibanski A
J Clin Endocrinol Metab; 1994 Jan; 78(1):89-93. PubMed ID: 8288721
[TBL] [Abstract][Full Text] [Related]
18. A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors.
Wierinckx A; Auger C; Devauchelle P; Reynaud A; Chevallier P; Jan M; Perrin G; Fèvre-Montange M; Rey C; Figarella-Branger D; Raverot G; Belin MF; Lachuer J; Trouillas J
Endocr Relat Cancer; 2007 Sep; 14(3):887-900. PubMed ID: 17914117
[TBL] [Abstract][Full Text] [Related]
19. Expression profiling of O(6) methylguanine-DNA-methyl transferase in prolactinomas: a correlative study of promoter methylation and pathological features in 136 cases.
Jiang XB; Hu B; He DS; Mao ZG; Wang X; Song BB; Zhu YH; Wang HJ
BMC Cancer; 2015 Sep; 15():644. PubMed ID: 26400193
[TBL] [Abstract][Full Text] [Related]
20. Expression of Neuropeptide Y and Its Relationship with Molecular and Morphological Changes in Human Pituitary Adenomas.
Jia R; Li M; Chang B; Chen L; Ma J
Cancer Biother Radiopharm; 2015 Dec; 30(10):411-9. PubMed ID: 26683132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
